Principal Financial Group Inc. Has $28.82 Million Stock Holdings in LifeStance Health Group, Inc. (NASDAQ:LFST)

Principal Financial Group Inc. grew its stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 6.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,116,766 shares of the company’s stock after purchasing an additional 235,316 shares during the period. Principal Financial Group Inc. owned approximately 1.08% of LifeStance Health Group worth $28,817,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in LFST. Point72 Asset Management L.P. acquired a new stake in LifeStance Health Group in the second quarter valued at approximately $4,326,000. Geode Capital Management LLC grew its position in LifeStance Health Group by 26.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,452,178 shares of the company’s stock valued at $24,170,000 after purchasing an additional 729,794 shares during the period. Wellington Management Group LLP increased its stake in LifeStance Health Group by 15.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,830,441 shares of the company’s stock valued at $33,813,000 after purchasing an additional 638,385 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in LifeStance Health Group by 82.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,016,452 shares of the company’s stock worth $4,991,000 after buying an additional 457,930 shares during the last quarter. Finally, Parkman Healthcare Partners LLC bought a new position in shares of LifeStance Health Group in the third quarter valued at $3,150,000. Institutional investors own 85.50% of the company’s stock.

Insider Transactions at LifeStance Health Group

In related news, Director Robert Bessler sold 75,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total transaction of $565,500.00. Following the sale, the director now directly owns 1,424,447 shares in the company, valued at approximately $10,740,330.38. The trade was a 5.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.60% of the company’s stock.

LifeStance Health Group Price Performance

Shares of LFST opened at $7.29 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $7.22 and a 200 day moving average of $6.42. LifeStance Health Group, Inc. has a 12 month low of $4.64 and a 12 month high of $9.20.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. The business had revenue of $312.70 million for the quarter, compared to analyst estimates of $302.25 million. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. As a group, analysts expect that LifeStance Health Group, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on LFST shares. Barclays boosted their target price on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research report on Monday, November 11th. The Goldman Sachs Group raised LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.70.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.